These studies suggest that alteration of DNA methylation at genomic loci closely related to the pathogenesis of IPF is a crucial factor in the development of IPF and that DNMT-targeted therapies could be a resource for remodeling this process, although further studies on their specificity and adverse effects are needed. This evidence concerns the gene DNMT1 and idiopathic pulmonary fibrosis.